Adverum is a gene therapy company advancing novel medicines that may offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Adverum Biotechnologies NASDAQ:
09/25/17 5:10 PM EDT
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Sep 7 2017
Summary ToggleAdverum Biotechnologies Appoints Eric G. Carter, M.D., Ph.D. to Board of Directors
- Sep 7 2017
Summary ToggleAdverum Biotechnologies to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference
- Aug 8 2017
Summary ToggleAdverum Biotechnologies Reports Second Quarter 2017 Financial Results and Provides Update
- Jun 20 2017
Summary ToggleAdverum Biotechnologies, Inc. Announces Appointment of Athena Countouriotis, M.D. as SVP and Chief Medical Officer
There are currently no events to display.